Pfizer issues first Trovan payouts; Watson plots new $23.5M distribution center;

@FiercePharma: 90% of surveyed MDs know about Incivek and Victrelis. Majority prescribe both. Report #sermosurveys | Follow @FiercePharma

> Pfizer made its first payments to parents of Nigerian children who died during a controversial trial of the meningitis drug Trovan. Report

> Watson Pharmaceuticals plans to build a $23.5 million, 234,000-square-foot distribution center in Mississippi to replace a leased facility in Ohio. Seventy people will be employed at the new building. Story

> Osmotica Pharmaceuticals plans to invest $20 million in a new manufacturing and R&D operation in Georgia, hiring 156 employees to take over work now farmed out to 5 contract manufacturers. News

> As expected, Avanir Pharmaceuticals sued generics makers Actavis and Par Pharmaceuticals to protect the patents on its new drug Nuedexta. Article 

> Generics maker Lannett has relaunched its morphine product with an FDA approval after the agency ordered it to stop selling the drug without clearance. Item 

> United Laboratories International, the largest penicillin producer in China, is shopping for $156 million in financing. Story

> The Mexican government certified two vaccines from China's Sinovac, including its seasonal flu shot. News

Biotech News

@FierceBiotech: VC groups proffer $14.4M to back Yaupon's lymphoma drug app. Item | Follow @FierceBiotech

@JohnCFierce: This is pretty cool. Blurring electronics and biology, Air Force and NSF create light "smart skin." Piece | Follow @JohnCFierce

@RyanMFierce: Osmotica Pharma is heading down to Georgia, putting R&D/manufacturing facility in Marietta. Story | Follow @RyanMFierce

@MaureenFierce: Dendreon's a Broken IPO, Again. News | Follow @MaureenFierce

> Proteon Therapeutics grabs $15.2M financing. News

> MannKind rallies on FDA nod for inhaled insulin trials. Item 

> Report: Biotech M&A activity jumps in 1H 2011. Report 

> LaMattina gives insider's view of R&D 'upheaval' at Pfizer. Article

> Icahn eyes leaner drug research at Forest, Bloomberg reports. Story 

And Finally... A broader mandate for meningitis vaccination in Texas is ruffling some conservative feathers. Report

Suggested Articles

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.

Biosims to Roche's Big 3 cancer drugs will chisel out a $10 billion sales gap by 2023, but newer meds could chip in $16.3 billion, the drugmaker says.